Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans

J Infect Dis. 2017 Sep 15;216(suppl_4):S555-S559. doi: 10.1093/infdis/jix001.

Abstract

Recently, novel highly pathogenic avian influenza H5Nx viruses (clade 2.3.4.4) caused outbreaks in US poultry. We evaluated the potential of a stockpiled A(H5N1) A/Anhui/1/2005 (clade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viruses. Sera from subjects who received 2 doses of MF59-adjuvanted A/Anhui/1/2005, or 1 dose of MF59-adjuvanted A/Anhui/1/2005 following priming with a clade 1 vaccine were characterized by microneutralization assays and modified hemagglutination inhibition (HI) assays. Only heterologous prime-boost vaccination induced modest cross-reactive HI antibody responses to H5Nx viruses. Heterologous prime-boost may provide a more effective vaccination strategy to broaden the antibody responses to emerging viruses.

Keywords: antibody responses; highly pathogenic avian influenza viruses; pre-pandemic stockpile.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adjuvants, Immunologic
  • Adolescent
  • Adult
  • Antibodies, Viral / blood
  • Antibody Formation*
  • Cross Reactions*
  • Dose-Response Relationship, Drug
  • Hemagglutination Inhibition Tests
  • Humans
  • Immunization, Secondary
  • Influenza A Virus, H5N1 Subtype / immunology*
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / therapeutic use*
  • Influenza, Human / prevention & control*
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Young Adult

Substances

  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Influenza Vaccines